Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine for Lymphatic Health in Alzheimer's Disease
NCT04205539Phase 1Withdrawn
- Sponsor
- Neurological Associates of West Los Angeles
- Start
- Dec 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of dexmedetomidine in Alzheimer's disease (AD), sponsored by Neurological Associates of West Los Angeles. Primary endpoints: T1 functional Magnetic Resonance Imaging and Diffusion Tensor Imaging. Planned start Dec 2021; status: withdrawn.
02
Drugs
dexmedetomidine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04205539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04205539.